spironolactone has been researched along with sacubitril in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clark, J; Gandotra, C; Liu, Q; Rose, M; Senatore, FF; Stockbridge, NL; Zhang, J | 1 |
| Ageev, FT; Ovchinnikov, AG | 1 |
| Bachir, N; Boukabous, A; Terki, A; Zaoui, N | 1 |
| Bernhardt, R; Chapa, J; Damera, N; George, B; Lee, E; Rao, RA; Reese, L; Shah, C | 1 |
4 other study(ies) available for spironolactone and sacubitril
| Article | Year |
|---|---|
Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Heart Failure; Humans; Spironolactone; Stroke Volume; Tetrazoles; United States; United States Food and Drug Administration; Valsartan; Ventricular Function, Left | 2022 |
[Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes].
Topics: Aminobutyrates; Amyloidosis; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Hypertrophy, Left Ventricular; Natriuretic Peptide, Brain; Phenotype; Spironolactone; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
[Impact of Dapagliflozin on echocardiographic parameters in patients with heart failure and reduced ejection fraction: "About a monocentric series of 43 cases"].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Echocardiography; Glucosides; Heart Failure; Humans; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Spironolactone; Stroke Volume | 2022 |
Using Sacubitril/Valsartan to Decrease Health care Costs in Population Health Patients.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Combinations; Health Care Costs; Heart Failure; Humans; Male; Medicare; Spironolactone; Stroke Volume; Tetrazoles; United States; Valsartan | 2023 |